Search by Drug Name or NDC
NDC 70518-3027-00 Hyoscyamine Sulfate 0.125 mg/1 Details
Hyoscyamine Sulfate 0.125 mg/1
Hyoscyamine Sulfate is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by REMEDYREPACK INC.. The primary component is HYOSCYAMINE SULFATE.
MedlinePlus Drug Summary
Hyoscyamine is used to control symptoms associated with disorders of the gastrointestinal (GI) tract. It works by decreasing the motion of the stomach and intestines and the secretion of stomach fluids, including acid. Hyoscyamine is also used in the treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Hyoscyamine may also be used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis (runny nose), and to reduce excess saliva production.
Related Packages: 70518-3027-00Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Hyoscyamine
Product Information
NDC | 70518-3027 |
---|---|
Product ID | 70518-3027_f6f1c70b-8ae4-f521-e053-6394a90a1ecb |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Hyoscyamine Sulfate |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Hyoscyamine Sulfate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 0.125 |
Active Ingredient Units | mg/1 |
Substance Name | HYOSCYAMINE SULFATE |
Labeler Name | REMEDYREPACK INC. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | UNAPPROVED DRUG OTHER |
Application Number | n/a |
Listing Certified Through | 2024-12-31 |
Package
NDC 70518-3027-00 (70518302700)
NDC Package Code | 70518-3027-0 |
---|---|
Billing NDC | 70518302700 |
Package | 90 TABLET in 1 BOTTLE, PLASTIC (70518-3027-0) |
Marketing Start Date | 2021-02-23 |
NDC Exclude Flag | N |
Pricing Information | N/A |